Therefore, future research should further evaluate this preliminary predictive capability of plasma S100b protein, Aβ40 peptide, and BDFN polymorphisms to identify cognitive vulnerability profiles in patients with MDD treated with ECT. The gene discussed is S100B; the disease is major depressive disorder.